Get the Stockscreener App
1.93
5.85%
-0.12
After Hours:
1.99
0.06
+3.11%
Inovio Pharmaceuticals Inc stock is traded at $1.93, with a volume of 386.81K.
It is down -5.85% in the last 24 hours and down -9.39% over the past month.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
See More
Previous Close:
$2.05
Open:
$2.01
24h Volume:
386.81K
Relative Volume:
0.38
Market Cap:
$69.67M
Revenue:
$832.00K
Net Income/Loss:
$-135.12M
P/E Ratio:
-0.3169
EPS:
-6.09
Net Cash Flow:
$-124.69M
1W Performance:
-1.53%
1M Performance:
-9.39%
6M Performance:
-71.66%
1Y Performance:
-82.84%
1-Day Range:
$1.91
$2.07
1-Week Range:
$1.88
$2.075
52-Week Range:
$1.74
$14.75
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
Name
Inovio Pharmaceuticals Inc
Sector
Industry
Phone
(858) 410-3134
Address
6769 MESA RIDGE RD., SAN DIEGO, PA
Compare INO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.93 | 69.67M | 832.00K | -135.12M | -124.69M | -6.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-24 | Initiated | Stephens | Overweight |
| Jan-25-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-09-22 | Downgrade | Maxim Group | Buy → Hold |
| Nov-01-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-19-22 | Resumed | RBC Capital Mkts | Sector Perform |
| May-11-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Dec-29-21 | Resumed | Jefferies | Hold |
| Sep-10-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-24-21 | Initiated | Jefferies | Hold |
| Mar-23-21 | Initiated | BofA Securities | Neutral |
| Feb-12-21 | Initiated | Oppenheimer | Outperform |
| Nov-17-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Nov-10-20 | Upgrade | ROTH Capital | Sell → Neutral |
| Sep-28-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-28-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-01-20 | Downgrade | Maxim Group | Buy → Hold |
| Jul-01-20 | Downgrade | ROTH Capital | Neutral → Sell |
| Jun-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-26-20 | Downgrade | Stifel | Buy → Hold |
| May-21-20 | Initiated | The Benchmark Company | Buy |
| Apr-30-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Mar-13-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-13-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-19-19 | Initiated | ROTH Capital | Buy |
| Feb-15-18 | Reiterated | Maxim Group | Buy |
| Oct-18-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Initiated | Citigroup | Buy |
| Jun-08-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-24-17 | Reiterated | Maxim Group | Buy |
| Mar-16-17 | Upgrade | Maxim Group | Hold → Buy |
| Mar-16-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
View All
Inovio Pharmaceuticals Inc Stock (INO) Latest News
INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 - PR Newswire
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025 - BioSpace
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
INOVIO Earnings Alert: Key Q4 and 2024 Financial Results Coming March 18What to Watch - StockTitan
Recurrent Respiratory Papillomatosis Market Set to Grow - openPR
Inovio Pharmaceuticals : to start global late-stage COVID-19 vaccine trial this summer -May 10, 2021 at 06:41 pm EDT - Marketscreener.com
Inovio Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch
Anus Neoplasms Treatment Market Size Report 2032 | Inovio - openPR
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) PT at $12.40 - Defense World
Inovio Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch
Inovio Pharmaceuticals (INO) Expected to Announce Earnings on Wednesday - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Cervical Dysplasia Market to Show Remarkable Growth Trends from - openPR
Inovio Pharmaceuticals to Host Third Quarter 2013 Earnings Webcast Live on Tuesday, November 12, 2013 - ACCESS Newswire
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Inovio Investor Alert: Class Action Lawsuit Filed - ACCESS Newswire
Inovio Pharma Stock Slips Ahead of Q3 Earnings: Retail’s Bullish - MSN
INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis - MyChesCo
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Urges Inovio Pharmaceuticals (INO) Investors with $100K Losses to Contact its Attorneys: Firm Investigating Possible Securities Fraud - ACCESS Newswire
INOVIO to Highlight Breakthrough Immunotherapy Data at AACR Conference - MSN
INO-3107 shows promise in reducing surgeries for RRP patients By Investing.com - Investing.com Canada
INOVIO Advances INO-3107 Into BLA Submission After Positive Phase 1/2 Trial Results For RRP - Nasdaq
INOVIO Announces Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as A Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications - Marketscreener.com
Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher - Zacks Investment Research
INO-3107 shows promise in reducing surgeries for RRP patients - Investing.com India
Inovio Pharmaceuticals' Phase 1/2 Study Results Published In Nature Communications - Marketscreener.com
Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications - PR Newswire
Zika Vaccines Market Poised for Breakthrough Growth by 2032 | Rising Demand & Key Innovations: Sanofi S.A, - EIN News
Immune Response Data For INO-3107 To Be Presented As A Poster At American Association For Cancer Research Immuno-Oncology Conference - Marketscreener.com
Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference - Quantisnow
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Brokerages Set Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Price Target at $12.40 - Defense World
DNA Nanotechnology Market Overall Study Report 2025-2032 | - openPR
BlackRock, Inc. Expands Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
Anal Cancer Market Forecast 2034: Clinical Trials, Medication, - openPR
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
INOVIO Reports Inducement Grant Under Inducement Plan - GuruFocus.com
INOVIO to Present at Oppenheimer Healthcare Life Sciences Conference - MyChesCo
Vanguard Group Inc. Reduces Stake in Inovio Pharmaceuticals Inc. - GuruFocus.com
INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - StreetInsider.com
Inovio Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Inc Stock (INO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):